Canadian Adult Congenital Heart Disease Intervention Registry (NCT04288596)
The Canadian Registry for Adults With Congenital Heart Disease Interventions
๐ฉบ Plain-English Summary (8th-Grade Level)
The ACHDi Registry study will create a foundational database for adult congenital heart disease interventions. This Pan-Canadian Registry will collect clinical and patient-reported information that will enable the evaluation of care processes and outcomes in five most common ACHDi interventions by enabling prospective and retrospective registry-based studies to answer important clinical practice and policy-relevant questions.
Who can join: Review the eligibility criteria below.
Location: Toronto General Hospital โ Toronto, Ontario
Age range: 18 Years to 110 Years
๐งช Interventions in This Study
- Participants undergoing ACHD intervention (OTHER)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Toronto General Hospital โ Toronto, Ontario
๐ Contact the Study Coordinator
Phone: (416) 634-8782
Email: lusine.abrahamyan@theta.utoronto.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Atrial Septal Defect clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.